These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34283399)

  • 1. Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.
    Aysal A; Agalar C; Egeli T; Unek T; Oztop I; Obuz F; Sagol O
    Endocr Pathol; 2021 Dec; 32(4):461-472. PubMed ID: 34283399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
    Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
    Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
    Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
    J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
    Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
    J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors.
    Botling J; Lamarca A; Bajic D; Norlén O; Lönngren V; Kjaer J; Eriksson B; Welin S; Hellman P; Rindi G; Skogseid B; Crona J
    Neuroendocrinology; 2020; 110(11-12):891-898. PubMed ID: 31658459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
    Kim JY; Lee SH; An S; Kim SJ; Sung YN; Song KB; Hwang DW; Kim SC; Hong SM
    Virchows Arch; 2018 May; 472(5):739-748. PubMed ID: 29666945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do morphologic characteristics play a role in nodal metastatic progression of well-differentiated pancreatic neuroendocrine tumors?
    Ugras N; Hasdemir S; Yerci Ö; Taşar P; Dündar HZ; Macunluoğlu AC
    Tumori; 2021 Feb; 107(1):80-85. PubMed ID: 32705937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
    Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
    Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
    Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
    Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of nectin-3 expression as a marker of tumor aggressiveness in pancreatic neuroendocrine tumor.
    Hirabayashi K; Tajiri T; Bosch DE; Morimachi M; Miyaoka M; Inomoto C; Nakamura N; Yeh MM
    Pathol Int; 2020 Feb; 70(2):84-91. PubMed ID: 31855317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD47 expression and CD163
    Imam R; Chang Q; Black M; Yu C; Cao W
    BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.